A clinical study spanning two years investigated the effects of the drug Bazedoxifene (Conbriza) at 10, 20 and 40 mg on postmenopausal women at risk for osteoporosis. The results showed positive indications for preventing bone loss and reducing bone turnover. What’s more is that the study demonstrated the drug’s safety profile and its use is not associated with endometrial, ovarian, and breast malignancy risks. In combination with conjugated estrogens, Bazedoxifene represents a novel therapeutic approach to the treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis.
Like many drugs that enter the pharmaceutical market, there’s still many stones left unturned. There are still a lot of questions left unanswered about this novel therapeutic agent and further scientific investigations are imperative if the drug is to survive future federal regulatory scrutiny. LGM Pharma recognizes the importance of such endeavors and is currently the market leader in supplying Bazedoxifene CAS# 198481-33-3 to large pharmaceutical companies who are involved in its research and development.
Santiago Palacios, MD, director of the Palacios Institute in Madrid, Spain, and colleagues conducted a study on more than 7,000 postmenopausal women with osteoporosis. The study population randomly received Bazedoxifene 20 mg or 40 mg daily, raloxifene (Evista) 60 mg daily or placebo for three years. The researchers also enrolled more than 4000 participants in an extension study (years four and five). The raloxifene group was discontinued in year four and women who received bazedoxifene 40 mg were shifted to bazedoxifene 20 mg at the end of year four. The overall findings of the study pointed to the Bazedoxifene’s safety profile at five years of use. According to the scientists, these results were consistent with those seen in the three-year core study. Furthermore, compared with the placebo, very few cases of endometrial carcinoma were seen in women assigned to bazedoxifene 20 mg or bazedoxifene 40/20 mg.
The drug, developed by Wyeth Pharmaceuticals, received marketing approval from the European Commission in April 2009 and is undergoing Phase III Trial in the US.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.